Opendata, web and dolomites

CRUZIVAX SIGNED

Vaccine for prevention and treatment of Trypanosoma cruzi infection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CRUZIVAX project word cloud

Explore the words cloud of the CRUZIVAX project. It provides you a very rough idea of what is the project "CRUZIVAX" about.

humoral    self    safety    mild    poor    decoy    immunogenicity    adjuvant    trial    locally    cruzivax    cellular    economic    interruption    gap    bridge    migration    antigen    symptoms    reducing    free    treatment    prophylactic    largely    activation    chronicity    stimulating    vi    lacking    unnoticed    chagas    chronic    trypanosoma    suburban    human    30    limited    parasitic    11    mass    cardiac    endemic    american    worldwide    cruzi    volunteers    immunity    disease    21    difficult    protect    immune    chimeric    mice    facilitated    strengthen    efficient    latin    conduct    cgmp    first    usa    infection    reports    profile    drug    efficacy    sequences    19    primates    therapy    infections    formulations    morbidity    carriers    americas    acute    perform    combined    dogs    gt    economics    trivalent    proven    social    million    engineered    active    rural    carry    formulation    settings    therapeutic    health    restricted    burden    needle    structure    clinical    became    000    critical    caused    pipeline    preclinical    healthy    benznidazole    models    countries    manufacturing    vaccine    performing   

Project "CRUZIVAX" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 0 €
 EC max contribution 8˙391˙240 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2024-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 2˙070˙198.00
2    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 963˙795.00
3    ASA SPEZIALENZYME GMBH DE (WOLFENBUTTEL) participant 951˙500.00
4    ATRC AURIGON TOXICOLOGIAI KUTATOKOZPONT KORLATOLT FELELOSSEGU TARSASAG HU (DUNAKESZI) participant 863˙592.00
5    GENIBET - BIOPHARMACEUTICALS SA PT (OEIRAS) participant 861˙249.00
6    UNIVERSIDAD DE BUENOS AIRES AR (BUENOS AIRES) participant 745˙500.00
7    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 577˙302.00
8    UNIVERSIDADE NOVA DE LISBOA PT (LISBOA) participant 442˙206.00
9    INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA PT (OEIRAS) participant 352˙356.00
10    VAKZINE PROJEKT MANAGEMENT GMBH DE (HANNOVER) participant 310˙137.00
11    FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA ES (BARCELONA) participant 253˙401.00

Map

 Project objective

Chagas is a neglected disease endemic in 21 Latin-American countries caused by Trypanosoma cruzi. It is the largest parasitic disease burden in the Americas (>11,000,000 chronic infections) and the first cause of cardiac morbidity in poor rural/suburban areas. It became a worldwide concern as a result of mass migration with reports in 19 non-endemic areas (>1.3 million carriers in EU/USA). Treatment is difficult since acute infections have mild symptoms and remain largely unnoticed evolving to chronicity. Drug therapy is also long, often associated with side effects (10-30% interruption) and only active during early infection. The main objective of CRUZIVAX is to bridge the gap between preclinical and clinical development by performing preclinical and clinical phase 1 studies of a needle-free vaccine against T. cruzi with proven efficacy in preclinical models. The vaccine is based on a structure-engineered trivalent chimeric antigen lacking immune decoy sequences and an adjuvant promoting self-limited locally-restricted immune activation stimulating humoral and cellular immunity, which is expected to protect as prophylactic or therapeutic (combined with Benznidazole) vaccine. To achieve this CRUZIVAX will: (i) conduct preclinical studies in mice to assess immunogenicity and efficacy of different vaccine formulations in prophylactic and therapeutic settings, (ii) analyse the immunogenicity and efficacy of the best vaccine formulation in dogs and non-human primates, (iii) produce cGMP antigen and adjuvant by cost-efficient manufacturing (facilitated uptake by health systems with limited resources), (iv) perform a preclinical safety assessment of the vaccine, (v) conduct a phase 1 vaccine clinical trial in healthy volunteers, and (vi) carry out a health economics analysis to identify critical target-product profile parameters. The vaccine will strengthen the pipeline of products for Chagas disease, aimed at reducing disease burden and its social and economic impact.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CRUZIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CRUZIVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More